Subtype
Esophageal Squamous Cell Carcinoma
CI-CAN-00002629ESCCExplore in graph →
212 active trials3 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002629ESCCExplore in graph →
Clinical trials
555 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (35)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05043688 | Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | active not recruiting | Phase 3 | 426 | Zhigang LiOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy(SKYSCRAPER-07) | completed | Phase 3 | 760 | Hoffmann-La RocheINDUSTRY | 28 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT03801876 | Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | active not recruiting | Phase 3 | 300 | NRG OncologyOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). | terminated | Phase 3 | 863 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 21, 2026 | clinicaltrials |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | recruiting | Phase 3 | 510 | Daiichi SankyoINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT07629817 | Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy(HCHTOG2603) | recruiting | Phase 3 | 1,044 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06304974 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) | active not recruiting | Phase 3 | 497 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | completed | Phase 3 | 703 | Merck Sharp & Dohme LLCINDUSTRY | 27 | Jul 22, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07487896 | A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy | recruiting | Phase 3 | 440 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07554456 | A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) | recruiting | Phase 2 / Phase 3 | 90 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07653451 | Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer(ESCC-PT) | not yet recruiting | Phase 2 / Phase 3 | 90 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07621601 | A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 3 | 494 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Jun 2, 2026 | clinicaltrials |
| NCT04550260 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC(KUNLUN) | active not recruiting | Phase 3 | 640 | AstraZenecaINDUSTRY | 16 | May 13, 2026 | clinicaltrials |
| NCT07463573 | QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 466 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07446335 | A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 578 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06952621 | Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma(TD-NEOE3V3) | not yet recruiting | Phase 3 | 390 | Tang-Du HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 737 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study | not yet recruiting | Phase 3 | 340 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 649 | BeiGeneINDUSTRY | 16 | Jul 29, 2025 | clinicaltrials |
| NCT07016737 | Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy(ESO-Nanjing12) | enrolling by invitation | Phase 3 | 79 | Ye jinjunOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04328948 | A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC(ARMADILLO) | recruiting | Phase 3 | 280 | National Cancer Center, JapanOTHER_GOV | 1 | May 22, 2025 | clinicaltrials |
| NCT06907602 | Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma(ONTRESCC) | recruiting | Phase 2 / Phase 3 | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06861777 | Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 / Phase 3 | 474 | YIN LIOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer(NEEDS) | recruiting | Phase 3 | 1,020 | Karolinska University HospitalOTHER | 5 | Mar 6, 2025 | clinicaltrials |
| NCT06775652 | Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC(ESCC) | completed | Phase 3 | 254 | Yongtao HanOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT05919030 | A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 155 | Renmin Hospital of Wuhan UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03430843 | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 512 | BeiGeneINDUSTRY | 11 | Oct 26, 2024 | clinicaltrials |
| NCT06656091 | A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 450 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 0 | Oct 24, 2024 | clinicaltrials |
| NCT05495152 | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 219 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06022861 | A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 510 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06563869 | Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06190782 | Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor | recruiting | Phase 3 | 354 | Fudan UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | recruiting | Phase 3 | 490 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05737563 | PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC(Escape) | unknown | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02465736 | Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308) | unknown | Phase 3 | 610 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03600831 | Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 434 | Huai'an First People's HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04187352 | A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 540 | CStone PharmaceuticalsINDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03748134 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) | completed | Phase 3 | 746 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Oct 24, 2023 | clinicaltrials |
| NCT03790553 | Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma | unknown | Phase 3 | 646 | Fudan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03958890 | A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 3 | 489 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT02025036 | Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer(CRTCOESC) | unknown | Phase 3 | 249 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05244798 | Sintilimab Plus NCT or NCRT Versus NCRT for ESCC | not yet recruiting | Phase 3 | 420 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | unknown | Phase 2 / Phase 3 | 90 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03623737 | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC | unknown | Phase 2 / Phase 3 | 248 | National Taiwan University HospitalOTHER | 1 | Jun 7, 2022 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials